31 December 2019 - - US-based immunotherapies developer CEL-SCI Corp. (NYSE American: CVM) announced the closing of an underwritten public offering of 606,395 shares of its common stock at a price of USD 9.07 per share, for total gross proceeds of approximately USD 5.5m, before deducting underwriting discounts and other offering expenses payable by the company.

Additionally, the company has granted the underwriter a 45-day option to purchase up to 90,959 additional shares to cover over-allotments.

Aegis Capital Corp. acted as the sole bookrunner for the offering.

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases.